A new kind of precision medicine for pancreatic cancer: what setidegrasib's "protein degrader" technology means for patients with the KRAS G12D mutation

If you or someone you love is facing pancreatic cancer, you already know how urgently we need better treatments. I want to share some genuinely encouraging news from a new class of drugs that work in a way we have never had before: instead of simply blocking a cancer-driving protein, they destroy it. The drug is called setidegrasib, and it specifically targets tumors carrying a mutation known as KRAS G12D. This is a different medicine, with a different mechanism, from daraxonrasib, which I discussed in an earlier article on this site. Both belong to an exciting new generation of RAS-targeted therapies, but they work differently and were tested in different patient groups, so let me walk you through what makes setidegrasib distinct, and what its early results actually show.

Understanding the target: what is KRAS G12D?

Much of pancreatic cancer's aggressiveness traces back to mutations in a gene called KRAS, which normally helps control how cells grow and divide. When KRAS is mutated, it can get stuck in an "on" position, driving the cancer cell to grow uncontrollably. KRAS G12D is one specific, well-recognized version of this mutation, and it is found in a meaningful subset of pancreatic cancers. For decades, KRAS was considered nearly "undruggable" because of its unusual shape, so having a medicine designed specifically against the G12D mutation is itself a significant scientific milestone.

What makes setidegrasib different: the "protein degrader" approach

Most targeted cancer drugs work like a lock that jams a protein's machinery, blocking it from functioning. Setidegrasib works differently. It is what scientists call a protein degrader: rather than just occupying the mutant KRAS G12D protein and holding it still, it tags the protein for the cell's own disposal system, which then breaks it down and clears it away entirely. Think of the difference between disabling a car's engine versus sending the whole car to the scrapyard. This is a first-in-class approach for this target, and it represents a genuinely new tool in our arsenal against a mutation that has long resisted treatment.

What the trial showed

These findings come from an international Phase I trial published in the New England Journal of Medicine in April 2026, led by Dr. Wungki Park of Memorial Sloan Kettering Cancer Center and Dr. Jonathan W. Goldman of UCLA, and funded by Astellas Pharma. This was a first-in-human, dose-finding study: 203 patients with advanced pancreatic cancer or non-small-cell lung cancer carrying the KRAS G12D mutation were enrolled between June 2022 and April 2025, and were given weekly doses ranging from as low as 10 mg up to 800 mg to determine the safest and most effective dose. Based on this careful escalation, researchers identified 600 mg weekly as the recommended dose for further study.

Among the 21 pancreatic cancer patients who received this 600 mg dose, all had already tried and stopped responding to prior treatments, meaning this was second- or third-line therapy for cancer that had already proven difficult to control. In this group, the objective response rate, meaning the proportion of patients whose tumors measurably shrank, was 24%. The median progression-free survival, or the typical length of time before the cancer began growing again, was 3.0 months, and median overall survival was 10.3 months. For context, the trial also enrolled 45 lung cancer patients with the same mutation, who showed a higher overall response rate of 36%; among the 32 lung cancer patients treated in the second- or third-line setting specifically, the response rate was 38%, with a median progression-free survival of 8.3 months and an estimated 59% of patients alive at 12 months. This likely reflects that KRAS G12D is more readily targetable in lung cancer, where the tumor biology is often less challenging than in pancreatic cancer.

Importantly, the safety profile at the 600 mg dose was manageable: 93% of patients experienced some degree of side effect, most commonly transient infusion-related reactions and nausea, but only 9% experienced a serious (grade 3 or higher) side effect, and just two patients had to stop treatment because of toxicity.

Why this matters for you and your family

I want to be clear about what this data does and does not tell us. This was a Phase I trial, meaning its main purpose was to establish safety and find the right dose, not to prove the drug extends life better than existing options. The encouraging response and survival numbers in pancreatic cancer are a real and meaningful signal, but they come from a small group of patients whose cancer had already progressed on other therapies, and larger, later-phase trials are needed before setidegrasib could become an approved, standard treatment.

What this study does underscore is the growing importance of molecular testing of your tumor. Identifying whether your pancreatic cancer carries a KRAS G12D mutation, or another specific driver mutation, is exactly how oncologists determine whether targeted therapies like this one might eventually be an option for you, whether through an approved treatment or a clinical trial. I encourage every patient and family member reading this to ask your oncology team about genetic or molecular testing of the tumor tissue, since this is increasingly becoming a standard and essential part of modern pancreatic cancer care.

The bottom line

Setidegrasib represents a genuinely novel approach, a protein degrader rather than a simple blocker, aimed at a specific, previously hard-to-treat mutation, KRAS G12D. Early Phase I results in pancreatic cancer show a real but modest signal of benefit with a manageable safety profile, in patients whose cancer had already resisted prior treatment. It is one of several new RAS-targeted medicines, each working differently, that are being studied for pancreatic cancer today, and together they reflect a broader and very hopeful shift toward precision medicine in this disease. As always, larger confirmatory trials are the next essential step, and the best way to know whether treatments like this could ever apply to you is to discuss genetic testing and current trial options directly with your oncologist.